Tumor Suppression
Tumor Suppression - Related Videos
08:34
The Measurement and Treatment of Suppression in Amblyopia
0 Views •
Cited by 54 •
2012
Amblyopia is a developmental disorder of the visual cortex that is often accompanied by strong suppression of one eye. We present a new technique for measuring and treating interocular suppression in patients with amblyopia that can be deployed using virtual reality goggles or a portable iPod Touch device.
02:43
Tumor Implantation and Injection of a Tumor Vaccine in a Mouse Model
0 Views •
2025
This video demonstrates a cell-based tumor vaccination assay. A mouse, intradermally injected with B16-F10 melanoma cells for tumor formation, is vaccinated with B16-F10 cells secreting Flt3L cytokine near the developed tumor. The secreted Flt3L from the vaccine promotes the maturation and proliferation of dendritic cells that then present tumor antigens to T cells in lymph nodes, triggering a targeted anti-tumor immune response.
04:29
Visualizing Transcriptional Suppression in Virus-Infected Cells
0 Views •
2026
Source: Kalveram, B. et al. Using Click Chemistry to Measure the Effect of Viral Infection on Host-Cell RNA Synthesis. J. Vis. Exp. (2013)This video demonstrates the use of click chemistry and fluorescence microscopy to visualize nascent RNA transcription in mammalian cells. It highlights how viral infection suppresses host transcription by comparing fluorescent signals between infected and control cells.
07:49
Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model
0 Views •
Cited by 15 •
2015
This protocol describes a method for the detailed evaluation of leukocyte subsets within the tumor microenvironment in a mouse tumor model. Chemerin-expressing B16 melanoma cells were implanted subcutaneously into syngeneic mice. Cells from the tumor microenvironment were then stained and analyzed by flow cytometry, allowing for detailed leukocyte subset analyses.
14:01
Human In Vitro Suppression as Screening Tool for the Recognition of an Early State of Immune Imbalance
0 Views •
2011
Tregs are potent suppressors of the immune system. There is a lack of unique surface markers to define them, hence, definitions of Tregs are primarily functional. Here we describe an optimized in vitro assay capable of identifying immune imbalance in subjects at risk to develop T1D.
FAQs
When DNA damage is detected, tumor-suppressive control can prevent a damaged cell from continuing toward proliferation. The affected cell may pause cell-cycle progression, undergo apoptosis, or enter cellular senescence, depending on the response engaged. These outcomes limit the chance that damaged genetic material will be passed through further cell divisions, making damage surveillance important for restricting cancer development.
Cell-cycle control, apoptosis, and senescence provide different layers of protection. Cell-cycle regulation can stop progression when growth is unsafe; apoptosis removes the affected cell; senescence creates a durable state in which the cell no longer proceeds through normal proliferation. Considering these outcomes separately helps cancer researchers interpret how disruption of one or more safeguards may change tumor behavior.
Loss of tumor-suppressor activity can occur through mutations, gene deletions, or reduced activity, and these changes do not have to be identical to produce a dangerous result. When critical controls are weakened, abnormal proliferation can proceed alongside genomic instability. This connection helps cancer researchers examine both the genetic status of suppressor genes and whether their encoded proteins remain functionally active.
Reduced activity can weaken growth control even when the corresponding gene remains present. Because tumor-suppressor genes encode proteins that monitor DNA damage, regulate cell-cycle progression, initiate apoptosis, or promote senescence, diminished function may compromise one or more safeguards. Recognizing this possibility prevents researchers from limiting their analysis to gene deletions and supports a broader evaluation of disrupted control pathways.
Researchers can examine whether tumor-suppressor genes show mutations, deletions, or reduced activity and then relate those disruptions to abnormal proliferation, genomic instability, or tumor development. This approach connects molecular changes with cancer-driving behavior rather than treating every genetic alteration as equally informative. It also provides a framework for prioritizing disrupted growth-control pathways for further study in cancer research.
Findings about disrupted tumor suppression can support biomarker development. A biomarker is a measurable feature used here to inform assessment of disease risk or prognosis. Because mutations, deletions, and reduced activity can indicate loss of growth control, their presence or functional consequences may help researchers distinguish biologically important changes from alterations with less direct relevance to disease progression.
Therapeutic strategies may focus on restoring disrupted growth-control pathways or exploiting the weaknesses created when those pathways fail. The first direction aims to recover safeguards that abnormal cells have lost, while the second uses the altered state as a point of therapeutic leverage. Tumor-suppression research therefore links molecular mechanism with treatment design by translating pathway disruption into potential therapeutic opportunities.